Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Bifidobacterium lactis is a probiotic bacterium that has been investigated for potential benefits in inflammatory bowel diseases (IBD), including Crohn’s Disease. Scientific evidence for its use is modest and not conclusive but does exist. Several small-scale studies and pilot clinical trials have examined probiotics—sometimes including B. lactis—in IBD patients. These studies often use mixed probiotic formulations rather than B. lactis alone, making it difficult to attribute effects specifically to this strain. Some data suggest that B. lactis may help modulate gut microbiota, reduce intestinal inflammation, and enhance mucosal barrier function, all of which could theoretically benefit Crohn’s patients. However, systematic reviews and meta-analyses generally conclude that, while probiotics may be beneficial in ulcerative colitis and for the prevention of pouchitis, evidence in Crohn’s Disease is weak or inconsistent. Major clinical guidelines do not currently recommend B. lactis or other probiotics as standard therapy for Crohn’s Disease, citing the need for more high-quality, strain-specific research. In summary, there is some scientific rationale and preliminary clinical evidence supporting the use of Bifidobacterium lactis in Crohn’s Disease, but the overall quality and quantity of evidence is limited, and routine use is not yet established.

More about Bifidobacterium lactis
More about Crohn's Disease

Other ingredients used for Crohn's Disease

Other health conditions supported by Bifidobacterium lactis

Products containing Bifidobacterium lactis